The modern therapy of systemic vasculitides: perspectives and challenges
- Authors: Novikov PI1, Zykova AS2, Moiseev SV1,2
-
Affiliations:
- Sechenov First Moscow State Medical University
- Lomonosov Moscow State University
- Issue: Vol 90, No 1 (2018)
- Pages: 76-85
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32707
- DOI: https://doi.org/10.17116/terarkh201890176-85
- ID: 32707
Cite item
Full Text
Abstract
Systemic vasculitis is a heterogeneous group of inflammatory diseases, which are classified according to the diameter of the affected vessels. The treatment of systemic vasculitis is no longer empirical, because of increasing number of randomized clinical trials in this field. In recent years, there was a trend to limit the cumulative dose of glucocorticosteroids and immunosuppressive drugs, partially through biological drugs usage. However, biologic therapy is not always superior to combination of glucocorticosteroids and cytotoxic drugs. The efficacy of different biologic drugs varies in patients with different forms of systemic vasculitis, which creates the ground forpersonalized therapy of these diseases. Another serious problem is the absence of strict criteria to immunosuppressive therapy intensification, especially in vasculitis, affecting large vessels, due to the lack of reliable laboratory markers of disease activity. The article reviews modern approaches to the treatment of some types of systemic vasculitis, including ANCA-associated vasculitides, giant cell arteritis, Takayasu`s arteritis and cryoglobulinemic vasculitis.
Full Text
##article.viewOnOriginalSite##About the authors
P I Novikov
Sechenov First Moscow State Medical Universityзав. отд-нием ревматологии УКБ №3
A S Zykova
Lomonosov Moscow State University
Email: ansezy@gmail.com
аспирант каф. внутренних болезней
S V Moiseev
Sechenov First Moscow State Medical University; Lomonosov Moscow State Universityпроф. каф. внутренних болезней факультета фундаментальной медицины МГУ им. М.В. Ломоносова
References
- Jennette J. Overview of the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Clinical and experimental nephrology. 2013;17(5):603-606. doi: 10.1007/s10157-013-0869-6
- Новиков П.И., Семенкова Е.Н., Моисеев С.В. Современная номенклатура системных васкулитов. Клиническая фармакология и терапия. 2013;22(1):70-74.
- Мухин Н.А., Розина Т.П, Новиков П.И. и др. Узелковый полиартериит, ассоциированный с вирусом гепатита В (клинический разбор). Клиническая медицина. 2015;93(6):5-13.
- Игнатова Т.М., Чернова О.А., Бурневич Э.З., Милованова С.Ю. Успешное лечение HCV-криоглобулинемического васкулита тяжелого течения с помощью CD-20 моноклональных антител и противовирусных препаратов. Клиническая медицина. 2014;92(8):62-64.
- Mukhtyar C, Guillevin L, Cid M, et al. EULAR recommendations for the management of large vessel vasculitis. Annals of the rheumatic diseases. 2009; 68(3):318-23. doi: 10.1136/ard.2008.088351
- Мухин Н.А., Мешков А.Д., Новиков П.И. и др. Гигантоклеточный артериит: клинические проявления и методы ранней диагностики. Клиническая фармакология и терапия. 2015;24(3):79-85.
- Мухин Н.А., Смитиенко И.О., Новиков П.И., Семенкова Е.Н., Моисеев С.В. Артериит Такаясу: трудности диганостики, лечение и исходы в когортном исследовании у 128 больных. Клиническая фармакология и терапия. 2014; 23 (3): 55-61.
- Kotter I, Henes J, Wagner A, Loock J, Gross W. Does glucocorticosteroid - resistant large - vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clinical and experimental rheumatology. 2012; 30(1)(suppl 70):114-29.
- Bienvenu B, Ly K, Lambert M, et al. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). La Revue de Médecine Interne. 2016;37(3):154-65. doi: 10.1016/j.revmed.2015.12.015
- Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant - cell arteritis: results of a multicentre randomised controlled trial. Annals of the rheumatic diseases. 2014;73(12):2074-2081. doi: 10.1136/annrheumdis-2013-203586
- Hoffman G, Cid M, Rendt-Zagar K, et al. Infliximab for maintenance of glucocorticosteroid - induced remission of giant cell arteritis: a randomized trial. Annals of internal medicine. 2007;146(9):621-630.
- Martínez-Taboada V, Rodríguez-Valverde V, Carreño L, et al. A double - blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Annals of the rheumatic diseases. 2008;67(5):625-630.
- Loricera J, Blanco R, Hernández J, et al. Tocilizumab in giant cell arteritis: Multicenter open - label study of 22 patients. Seminars in arthritis and rheumatism. 2015; 44(6):717- 723. doi: 10.1016/j.semarthrit. 2014.12.005
- Régent A, Redeker S, Deroux A, et al. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients. The Journal of rheumatology. 2016;43(8):1547-1552. doi: 10.3899/jrheum.151252
- Villiger P, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double - blind, placebo - controlled trial. The Lancet. 387(10031):1921-1927. doi: 10.1016/S0140-6736(16)00560- 2
- Сатыбалдыев А.М., Сатыбалдыева М.А., Насонов Е.Л. Тоцилизумаб в лечении ревматической полимиалгии и гигантоклеточного артериита. Клиническая фармакология и терапия. 2017;26(1):47-53.
- Stone J, Tuckwell K, Dimonaco S, et al. Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Paper presented at: ACR/ARHP 2016 Annual Meeting. November 13, 2016. Available at: http://acrabstracts.org/abstract/efficacy-and-safety-of-tocilizumab-in-patients-with-giant-cell-arteritis-primary-and-secondary-outcomes-from-a-phase-3-randomized-double-blind-placebo-controlled-trial/. Accessed March 27, 2017.
- Conway R, O'Neill L, O'Flynn E, et al. Ustekinumab for the treatment of refractory giant cell arteritis. Annals of the rheumatic diseases. 2016; 75(8):1578-1579. doi: 10.1136/annrheumdis-2016-209351
- Langford C, Cuthbertson D, Ytterberg S, et al. A randomized, double - blind trial of abatacept (CTLA4-IG) for the treatment of giant cell arteritis. Arthritis & Rheumatology. [Epub ahead of print] doi: 10.1002/art.40044
- Novikov P, Meshkov A, Moiseev S. Positron emission tomography in giant cell arteritis: a new diagnostic tool? Annals of the Rheumatic Disease. 2014;73(11):e70. doi: 10.1136/annrheumdis-2014-206227
- Hoffman G, Merkel P, Brasington R, Lenschow D, Liang P. Anti - tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis and rheumatism. 2004;50(7): 2296-2304. doi: 10.1002/art.20300
- Comarmond C, Plaisier E, Dahan K, et al. Anti TNF-alpha in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmunity reviews/ 2012; 11(9):678-684. doi: 10.1016/j.autrev. 2011. 11.025
- Новиков П.И., Смитиенко И.О., Моисеев С.В. Эффективность продолжительного лечения ингибиторами фактора некроза опухоли - α при артериите Такаясу, рефрактерном к стандартной иммуносупрессивной терапии. Клиническая фармакология и терапия. 2013;22(2):44-48.
- Novikov P, Smitienko I, Moiseev S. Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature. Clinical rheumatology. 2013;32(12):1827-1832. doi: 10.1007/s10067-013-2380-6
- Loricera J, Blanco R, Hernandez J, et al. Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clinical and Experimental Rheumatology. 2016; 34(3) (suppl 97):44-53.
- Park M, Lee S, Park Y, Lee S. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford, England). 2006; 45(5):545-548. doi: 10.1093/rheumatology/ kei266
- Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti - interleukin-6 receptor antibody. Arthritis and rheumatism. 2008;58(4):1197-1200. doi: 10.1002/art.23373
- Mekinian A, Comarmond C, Resche-Rigon M, et al. Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients. Circulation. 2015;132(18):1693-1700. doi: 10.1161/circulationaha.114.014321
- Langford C, Cuthbertson D, Ytterberg S, et al. A randomized, double - blind trial of abatacept (CTLA4-ig) for the treatment of Takayasu's arteritis. Arthritis & Rheumatology. 2017 [epub ahead of print]. doi: 10.1002/art.4003
- O’Connor T, Carpenter H, Bidari S, Waters M, Hedna V. Role of inflammatory markers in Takayasu arteritis disease monitoring. BMC Neurology. 2014; 14:62. doi: 10.1186/1471-2377-14-62
- Smitienko I, Atyasova E, Moiseev S, Novikov P. MR Angiography for Evaluation of Vascular Inflammation in Patients with Takayasu's Arteritis. Paper presented at: The 18th Inernational Vasculitis and ANCA Workshop. March 25-28, 2017. Available at: http://www.anca2017. tokyo/abstracts.html. Accessed March 27, 2017.
- Nakagomi D, Jayne D. Outcome assessment in Takayasu arteritis. Rheumatology (Oxford). 2016; 55(7):1159-71. doi: 10.1093/rheumatology/kev366
- Goglin S, Chung S. Current Treatment of Cryoglobulinemic Vasculitis. Current Treatment Options in Rheumatology. 2016;2(2):213-224. doi: 10.1007/s40674-016- 0048-5
- Ferri C, Greco F, Longombardo G, et al. Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. Clinical and experimental rheumatology. 1991; 9(6):621-624.
- Милованова C.Ю., Козловская Л.В., Гордовская Н.Б. Полиморфизм клинических проявлений риоглобулинемического васкулита, ассоциированного с хроническим гепатитом С. Альманах клинической медицины. 2014; 30:46-51. doi: 10.18786/2072- 0505-2014-30-46-51
- Ignatova T, Chernova O, Novikov P, Moiseev S. HCV-associated cryoglobulinaemic vasculitis: triple/dual antiviral treatment and/or rituximab? Annals of the rheumatic diseases. 2014; 73(9):e58. doi: 10.1136/annrheumdis-2014-205997.
- Saadoun D, Thibault V, Si Ahmed S, et al. Sofosbuvir plus ribavirin for hepatitis C virus - associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Annals of the rheumatic diseases. 2016;75(10):1777-1782. doi: 10.1136/annrheumdis-2015-208339
- Ferri C, Giuggioli D, Cazzato M, Sebastiani M, Mascia M, Zignego A. HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. Clinical and experimental rheumatology. 2003; 21(6)(suppl 32):78-84.
- De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis and rheumatism. 2012; 64(3):843-853. doi: 10.1002/art. 34331
- Saadoun D, Resche Rigon M, Pol S, et al. PegIFNalpha/ribavirin/protease inhibitor combination in severe hepatitis C virus - associated mixed cryoglobulinemia vasculitis. Journal of hepatology. 2015; 62(1):24-30. doi: 10.1016/j.jhep.2014.08.015
- Saadoun D, Thibault V, Si Ahmed S, et al. Sofosbuvir plus ribavirin for hepatitis C virus - associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Annals of the rheumatic diseases. 2016; 75(10): 1777-82. doi: 10.1136/annrheumdis-2015-208339
- Bonacci M, Lens S, Londoño M, et al. Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. Clinical Gastroenterology and Hepatology. 2017;15(4):575-583. doi: 10.1016/j.cgh.2016.09.158
- Landau D, Saadoun D, Halfon P, et al. Relapse of hepatitis C virus - associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis & Rheumatism. 2008; 58(2):604-611. doi: 10.1002/art.23305
- Artemova M, Abdurakhmanov D, Ignatova T, Mukhin N. Persistent HCV-associated Cryoglobulinemic Vasculitis Following Virus Eradication after Direct-Acting Antivirals Therapy. Hepatology. 2016; [epub ahead of print]. doi: 10.1002/hep.28981
- Moiseev S, Novikov P, Mukhin N. HCV-associated cryoglobulinemia vasculitis: are its days numbered? Annals of the rheumatic diseases.2017;76(3):5. doi: 10.1136/annrheumdis-2016-210636
- Novikov P, Smitienko I, Bulanov N, Zykova A, Moiseev S. Testing for antineutrophil cytoplasmic antibodies (ANCAs) in patients with systemic vasculitides and other diseases. Annals of the rheumatic diseases. 2016; (epub ahead of print). doi: 10.1136/annrheumdis-2016-210890
- Damoiseaux J, Csernok E, Rasmussen N, et al. Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen - specific immunoassays. Annals of the rheumatic diseases. 2016; 76(4):647-653. doi: 10.1136/annrheumdis-2016-209507
- Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Annals of the rheumatic diseases. 2008;67(7):1004-1010. doi: 10.1136/ard.2007.071936
- Flossmann O, Berden A, de Groot K, et al. Long - term patient survival in ANCA- associated vasculitis. Annals of the rheumatic diseases. 2011; 70(3):488-494. doi: 10.1136/ard.2010.137778
- Novikov P, Moiseev S, Kuznetsova E, Semenkova E, Mukhin N. Changing patterns of clinical severity and risk of mortality in granulomatosis with polyangiitis over four decades: the Russian experience. Rheumatology International. 2015; 35(5):891-898. doi:10.1007/ s00296-014-3154-4
- Hoffman G, Kerr G, Leavitt R, et al. Wegener granulomatosis: an analysis of 158 patients. Annals of internal medicine. 1992;116(6): 488-498. doi: 10.7326/0003-4819- 116-6-488
- Faurschou M, Sorensen I, Mellemkjaer L, et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. The Journal of rheumatology. 2008; 35(1):100-105.
- de Groot K, Harper L, Jayne D, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody - associated vasculitis: a randomized trial. Annals of internal medicine. 2009; 150(10):670-680. doi: 10.7326/0003-4819-150-10-200905190-00004
- Harper L, Morgan M, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long - term follow - up. Annals of the rheumatic diseases. 2012; 71(6):955-960. doi: 10.1136/annrheumdis-2011-200477
- Jayne D, Rasmussen N, Andrassy K, et al. A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies. New England Journal of Medicine. 2003; 349(1):36-44. doi: 10.1056/NEJMoa020286
- Stone J, Merkel P.A, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA- associated vasculitis. The New England journal of medicine. 2010; 363(3):221-232. doi: 10.1056/NEJMoa0909905
- Jones R, Tervaert J, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA- associated renal vasculitis. The New England journal of medicine. 2010; 363(3):211-220. doi: 10.1056/NEJMoa 0909169
- Yates M, Watts R, Bajema I, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Annals of the rheumatic diseases. 2016;75(9):1583-1594. doi: 10.1136/annrheumdis-2016-209133
- Новиков П.И., Зыкова А.С., Смитиенко И.О., Моисеев С.В. Лечение АНЦА- ассоциированных васкулитов: рекомендации EULARERA-EDTA 2016 года. Клиническая фармакология и терапия. 2017;26(1):80-87.
- Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. The New England Journal of Medicine. 2014;371(19):1771-1780. doi: 10.1056/NEJMoa1404231
- Бекетова Т.В., Александрова Е.Н, Новоселова Т.М. и др. Российский опыт применения моноклональных антител к В-лимфоцитам (Ритуксимаб) при системных васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами (предварительные результаты российского регистра НОРМА). Научно - практическая ревматология. 2014;52(2):147-158. doi: 10.14412/1995-4484-2014-147-158
- Ананьева Л.П., Соловьев С.К., Бекетова Т.В. и др. Анти-В-клеточная терапия при иммуновоспалительных ревматических заболеваниях: эффективность и переносимость у 229 больных. Научно - практическая ревматология. 2014;52(5):495-506. doi: 10.14412/1995-4484-2014-495-506
- Novikov P, Moiseev S, Shevtsova T, Smitienko I. Short - term Efficacy and Safety of Biosimilar Rituximab in Patients with Systemic Vasculitides. Paper presented at: The 18th Inernational Vasculitis and ANCA Workshop. March 25-28, 2017. Available at: http://www.anca2017. tokyo/abstracts.html. Accessed March 27, 2017.
- Walsh M, Merkel P, Peh C, et al. Plasma exchange and glucocorticoid dosing in the treatment of anti - neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials. 2013;14:3. doi: 10.1186/1745-6215- 14-73
- Lenert A, Lenert P. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug design, development and therapy. 2015; 9: 333-347. doi: 10.2147/DDDT.S67264
- Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Annual review of immunology. 2003; 21:231-264. doi: 10.1146/annurev.immunol.21.120601.141152
- Schiemann B, Gommerman J, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science (New York, NY). 2001;293(5537):2111-2114. doi: 10.1126/science.1061964
- Bamberg C, Mackay C, Lee H, et al. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. The Journal of biological chemistry. 2010; 285(10):7633-7644. doi: 10.1074/jbc. M109.092106
- Jayne D, Bruchfeld A, Harper L, et al. MO039Successful steroid replacement in ANCA-associated vasculitis with C5A receptor inhibitor CCX168 in phase 2 randomised (CLEAR). Nephrology Dialysis Transplantation. 2016; 31(suppl 1):45. doi: 10.1093/ndt/gfw137.01
- Merkel P.A, Niles J, Jimenez R, et al. A Randomized Clinical Trial of CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with ANCA-Associated Vasculitis [abstract]. Arthritis and Rheumatology. 2016; 68 (suppl 10). Paper presented at: 2016 ACR/ARHR Annual Meeting. November 13, 2016. Available at: http://acrabstracts.org/abstract/a-randomized-clinical-trial-of-ccx168-an-orally- administered-c5ar-inhibitor-for-treatment-of-patients-with-anca-associated- vasculitis/.Accessed March 27, 2017.
- Novikov P, Moiseev S, Bulanov N, Shchegoleva E. Bortezomib in refractory ANCA- associated vasculitis: a new option? Annals of the rheumatic diseases. 2016;75(1):9. doi: 10.1136/annrheumdis-2015-207947
- Тареев Е.М., Семенкова Е.Н. Астматический вариант узелкового периартериита. Клиническая медицина. 1969;7:28-34.
- Семенкова Е.Н. Системные васкулиты. Москва: Медицина, 1988.
- Загвоздкина Е.С., Новиков П.И., Моисеев С.В. Особенности клинических проявлений и течения эозинофильного гранулематоза с полиангиитом в зависимости от наличия антител к цитоплазме нейтрофилов. Клиническая фармакология и терапия. 2017;26(1):24-30.
- Sinico R, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis and Rheumatism. 2005;52(9):2926-2935. doi: 10.1002/art.21250
- Cottin V, Bel E, Bottero P, et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg- Strauss). Autoimmunity Reviews. 2017;16(1):1-9. doi: 10.1016/j.autrev.2016.09.018
- Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA). Consensus Task Force recommendations for evaluation and management. European journal of internal medicine. 2015; 26(7):545-553. doi: 10.1016/j.ejim. 2015.04. 022
- Puéchal X, Pagnoux C, Baron G, et al. Prevent relapses in patients with systemic necrotizing vasulitides without poor - prognosis factors? A multicenter, double - blind randomized controlled trial. Annals of the rheumatic diseases. 2016; 75(suppl 2):77. doi: 10.1136/annrheumdis-2016-eular.6204
- Moiseev S, Novikov P. Five Factor Score in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA): to use or not to use? Annals of the rheumatic diseases. 2014;73(3)e.12. doi: 10.1136/annrheumdis-2013-204809
- Mohammad A, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) Annals of the Rheumatic Diseases. 2016;75:396-401. doi: 10.1136/annrheumdis-2014-206095
- Novikov P, Moiseev S, Smitienko I, Zagvozdkina E. Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: A report of 6 cases. Joint, bone, spine. 2016;83(1):81-84. doi: 10.1016/j.jbspin.2015.04.016
- Novikov P, Moiseev S. Biologic therapy for eosinophilic granulomatosis with polyangiitis: comment on the article by Jachiet et al. Arthritis & Rheumatology. 2016; [Epub ahead of print] doi: 10.1002/art.40015
- Jachiet M, Samson M, Cottin V, et al. Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients. Arthritis & rheumatology (Hoboken, NJ). 2016; 68(9): 2274- 2282. doi: 10.1002/art.39663